Due to the contribution of the CCL2/CCR2 and CXCL1/CXCR2 axes to the pathology of various cancers, there have been attempts to develop CCR2 and CXCR2 antagonists, anticipating therapeutic benefits from CCR2 and CXCR2 inhibition. Here, CCR2 is linked to cancer.